BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 15324713)

  • 1. Treatment options in irritable bowel syndrome.
    Farthing MJ
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The brain-gut axis in irritable bowel syndrome--clinical aspects.
    Mach T
    Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; BoznaƄska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
    Cremonini F; Talley NJ
    Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapeutical approaches for treatment of irritable bowel syndrome].
    Siegert F; Nieber K
    Med Monatsschr Pharm; 2010 Aug; 33(8):285-92; quiz 293-4. PubMed ID: 21189648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?
    Crentsil V
    Med Hypotheses; 2005; 65(1):97-102. PubMed ID: 15893125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
    Komoto S; Miura S
    Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic therapy for the irritable bowel syndrome.
    Talley NJ
    Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel syndrome: new and emerging therapies.
    Harris LA; Chang L
    Curr Opin Gastroenterol; 2006 Mar; 22(2):128-35. PubMed ID: 16462168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in the treatment of irritable bowel syndrome.
    De Schryver AM; Samsom M
    Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
    Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment.
    Chang JY; Talley NJ
    Trends Pharmacol Sci; 2010 Jul; 31(7):326-34. PubMed ID: 20554042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spectrum of irritable bowel syndrome: A clinical review.
    Gilkin RJ
    Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of irritable bowel syndrome. A case control experience.
    Astegiano M; Pellicano R; Terzi E; Simondi D; Rizzetto M
    Minerva Gastroenterol Dietol; 2006 Dec; 52(4):359-63. PubMed ID: 17108865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.